More Articles

How will biosimilars be affected by the TPP Policies & Legislation | Posted 09/10/2015

Since 2009, the US Government has been negotiating a free-trade agreement known as the Trans-Pacific Partnership (TPP) with 11 other countries across the Asia-Pacific and Latin American regions. Th...

Mylan goes after Perrigo Pharma News | Posted 09/10/2015

US generics manufacturer Mylan announced on 14 September 2015 that it had officially commenced its formal offer to acquire all outstanding ordinary shares of rival Ireland-based generics maker Perr...

Allergan makes deal with Amneal over its Namenda XR generic Generics/News | Posted 09/10/2015

Allergan has gained some breathing space for the extended-release version of its blockbuster Alzheimer’s disease treatment Namenda XR (memantine XR) after making a deal to delay generics entry for...

Another infliximab switching trial started Biosimilars/News | Posted 02/10/2015

In The Netherlands another study has been initiated into the effects of switching patients from originator infliximab to biosimilar infliximab.

Biosimilar epoetin-α as effective as originator in anaemia treatment Biosimilars/Research | Posted 02/10/2015

A study by researchers in Italy has concluded that biosimilar epoetin‑α appears to be comparable to originator epoetin‑α plus liposomal iron (Sideral), vitamin B12 and folates in terms of efficacy...

German physicians not pressured to switch to biosimilar infliximab Reports | Posted 02/10/2015

Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research a...

Formulation differences between generics and reference products Generics/Research | Posted 02/10/2015

Authors from the Office of Generic Drugs at the US Food and Drug Administration (FDA) highlight general toxicology concerns caused by formulation differences between generic and originator drugs [1].

Biosimilar etanercept safe and effective Biosimilars/Research | Posted 02/10/2015

In a study funded by Samsung Bioepis (a Biogen and Samsung joint venture), their candidate etanercept biosimilar (SB4) has been found to be safe and well tolerated and to be equivalent in terms of...